Category: Fellows Posters
The Kidney Disease Improving Global Outcomes (KDIGO) guideline recognizes the importance of balancing the benefits of reducing blood transfusions and anemia-related symptoms against the risks of harm to patients with chronic kidney disease when utilizing erythropoiesis stimulating agents. The purpose of this study is to assess the appropriateness of dosage, dosing frequency, efficacy, safety and dose titration of darbepoetin use at an ambulatory dialysis clinic associated with a safety–net hospital.
This retrospective medical record evaluation has been submitted to the Institutional Review Board for approval. Patients will be identified using automated dispensing cabinet reports of darbepoetin doses over a six-month period, January through June 2019. Patient demographic data will be extracted from the electronical medical record as well as baseline and ongoing labs (including hemoglobin, mean corpuscular volume, ferritin, and transferrin saturation). Dosing titrations based on hemoglobin response, iron stores, and frequency of blood transfusion will also be assessed. Descriptive statistics will be utilized to delineate the response based on iron stores of responders vs non responders (difference in two groups). Data from patients with optimal hemoglobin levels will be reviewed to evaluate appropriate darbepoetin management. Use of darbepoetin in each patient will be evaluated as optimal or suboptimal based on KDIGO guidelines and manufacturer recommendations.